[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655744":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":17,"studyPopulation":18,"armGroups":19,"interventions":25,"overallOfficials":13,"centralContacts":32,"locations":38,"responsibleParty":55,"collaborators":13,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":13,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":13,"enrollmentInfo":66,"targetDuration":13,"studyType":69,"phases":13,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":41,"whyStopped":13,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Glaukos Corporation","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Successful administration of iDose TR in an office-based surgical setting.","Number of subjects that received iDose TR in an office-based surgical setting by the Investigator.","3 months",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"COHORT","PROSPECTIVE","This study is a multicenter, single arm, open-label trial in adult subjects with open-angle glaucoma or ocular hypertension. The objective of the study is to assess the safety profile of iDose TR administration in an office-based surgery setting.","Adults 18 years of age or older with open-angle glaucoma or ocular hypertension",[20],{"label":21,"type":13,"description":22,"interventionNames":23},"iDose TR","Travoprost Intracameral Implant",[24],"Combination Product: iDose TR (travoprost intracameral implant) 75 µg",[26],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"COMBINATION_PRODUCT","iDose TR (travoprost intracameral implant) 75 µg","Travoprost-releasing implant preloaded in a sterile, single-use inserter.",[21],[21],[33],{"name":34,"role":35,"phone":36,"phoneExt":13,"email":37},"Study Director","CONTACT","949-739-8749","ClinicalResearch@glaukos.com",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Glaukos Investigative Site","RECRUITING","Austin","Texas","78746","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-97.74306,30.26715,{"lat":51,"lon":50},[54],{"name":40,"role":35,"phone":36,"phoneExt":13,"email":37},{"type":56,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100655744","idose-tr-administration-in-an-office-based-surgery-setting-100655744",false,"NCT07816692","iDose TR Administration in an Office-Based Surgery Setting","Real-World Evidence Observational Study to Evaluate the Safety of iDose® TR (Travoprost Intracameral Implant) 75 µg in an Office-Based Surgery Setting","Inclusion Criteria:\n\n* Diagnosis of Open angle glaucoma (OAG) or ocular hypertension (OHT)\n\nExclusion Criteria:\n\n* Prior administration of iDose TR or administration of an investigational intracameral implant in the study eye\n* Active ocular infection or inflammation\n* History of hypersensitivity to travoprost or implant components\n* Recent ocular surgery\n* Uncontrolled systemic disease\n* Any condition preventing safe implantation","ALL","18 Years",{"count":67,"type":68},30,"ESTIMATED","OBSERVATIONAL","Clinical in-use observational trial to evaluate the administration of iDose TR (travoprost intracameral implant) in an office-based surgery setting.",[72,73],"Open Angle Glaucoma (OAG)","Ocular Hypertension (OHT)",[75,76],"Glaucoma","Ocular Hypertension","2026-09-29",{"date":79,"type":80},"2026-09-30","ACTUAL",{"date":82,"type":80},"2026-05-13",{"date":84,"type":68},"2027-03",{"name":5,"class":6},1]